These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 38675679)

  • 1. A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action.
    Zhang S; Ren X; Zhang B; Lan T; Liu B
    Molecules; 2024 Apr; 29(8):. PubMed ID: 38675679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease.
    Doumas M; Imprialos K; Dimakopoulou A; Stavropoulos K; Binas A; Athyros VG
    Curr Pharm Des; 2018; 24(38):4587-4592. PubMed ID: 30652643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statins in nonalcoholic fatty liver disease and steatohepatitis: updated review.
    Nseir W; Mahamid M
    Curr Atheroscler Rep; 2013 Mar; 15(3):305. PubMed ID: 23328905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins for the Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis.
    Dai W; Xu B; Li P; Weng J
    Am J Ther; 2023 Jan-Feb 01; 30(1):e17-e25. PubMed ID: 36608070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
    Doumas M; Imprialos K; Stavropoulos K; Athyros VG
    Curr Vasc Pharmacol; 2019; 17(5):425-428. PubMed ID: 31418344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options?
    Papademetriou M; Athyros VG; Geladari E; Doumas M; Tsioufis C; Papademetriou V
    Curr Vasc Pharmacol; 2018; 16(3):254-268. PubMed ID: 28676027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Cholesterol-Associated Steatohepatitis in the Development of NASH.
    Horn CL; Morales AL; Savard C; Farrell GC; Ioannou GN
    Hepatol Commun; 2022 Jan; 6(1):12-35. PubMed ID: 34558856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial.
    Bril F; Portillo Sanchez P; Lomonaco R; Orsak B; Hecht J; Tio F; Cusi K
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2950-2961. PubMed ID: 28575232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?
    Paschos P; Athyros VG; Tsimperidis A; Katsoula A; Grammatikos N; Giouleme O
    Curr Vasc Pharmacol; 2018; 16(3):269-275. PubMed ID: 28676018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic fatty liver disease and statins.
    Tziomalos K; Athyros VG; Paschos P; Karagiannis A
    Metabolism; 2015 Oct; 64(10):1215-23. PubMed ID: 26234727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pleiotropic Effects of Statins in the Light of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis.
    Ahsan F; Oliveri F; Goud HK; Mehkari Z; Mohammed L; Javed M; Althwanay A; Rutkofsky IH
    Cureus; 2020 Sep; 12(9):e10446. PubMed ID: 33072455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.
    Caldwell S
    Clin Mol Hepatol; 2017 Jun; 23(2):103-108. PubMed ID: 28494529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statins and nonalcoholic fatty liver disease: a bright future?
    Athyros VG; Katsiki N; Karagiannis A; Mikhailidis DP
    Expert Opin Investig Drugs; 2013 Sep; 22(9):1089-93. PubMed ID: 23889731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes.
    Nascimbeni F; Pellegrini E; Lugari S; Mondelli A; Bursi S; Onfiani G; Carubbi F; Lonardo A
    Atherosclerosis; 2019 May; 284():66-74. PubMed ID: 30875495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.